_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
Lemaitre Vascular, Inc. (XNAS:LMAT) In-Depth Stock/Fundamental/Options Analysis Today
Primary Facts
LMAT
Name:
LEMAITRE VASCULAR, INC. (XNAS:LMAT)
Sector:
4.18M
Industry:
Medical Instruments & Supplies
CEO:
Mr. George LeMaitre
Total Employees:
450
Our Technological Advancement Rating
Our Rating:
D
Technological advancement compared to industry is -133.15% lower
ANALYSIS OF ALL CRITICAL FACTORS & RISKS RELATED TO THE STOCK & FUNDAMENTAL/LONG-TERM ANALYSIS OF LEMAITRE VASCULAR, INC.(LMAT) AS PER DATA ANALYSIS OF LAST 3 YEARS AND COMPARISON WITH COMPETITORS/PEERS, AND MEDICAL INSTRUMENTS & SUPPLIES INDUSTRY. DATE: 07/09/2022
Primary Targets/Price Insights
Previous Close ($) :
49.26
One Month Price Target:
$49.59
Six Month Price Target :
$51.23
Likely Price in One Year's Time:
Ticker:
$53.2
Likely Trading Range Today Under (Normal Volatility)
$49.06
Price Upper limit ($) :
$49.55
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
$46.39
This week:
$42.85
This month :
$36.44
Other Primary facts
Market Cap:
1.07B
Market Cap Classification:
Small Cap
Number of Shares
IPO Date:
21.96M
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
14.9%
-19.51%
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$62.55
$56.41
$35.97
$42.11
Medium risk (<10%) entry points
Buy Call
Sell Call
$54.41
Buy Put:
Sell Put:
$53.10
$44.10
$45.42
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
LMAT
Sharpe Ratio:
2.90%
Comparison:
LMAT, is amongst the top 40% stocks with highest risk-adjusted returns
Sharpe ratio is 80.93% higher than the industry
& ratio is 27.10% higher than the market/S&P 500 average
Average Returns/Yield of
LMAT
Daily returns:
0.09%
Weekly returns:
0.46%
Monthly returns:
1.84%
Yearly returns:
14.68%
Comparison of returns:
Average annual returns/yield (last 3 years) is 50.76% above industry average
Classification:
LMAT, is amongst the top 40% highest yielding stocks in terms of daily returns
Results of T-Test of Returns:
0.79
Statistical test of Returns:
LMAT has not yielded statistically significant higher returns when compared to the market
Volatility (measured by Standard Deviation)
Daily Volatility:
2.88%
Weekly Volatility:
6.44%
Monthly Volatility:
12.87%
Yearly Volatility:
44.59%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
0.92%
Volatility in last five trading days has been -67.96% below long-term volatility
Value at Risk Analysis (VaR)
Daily VaR:
-5.82%
Weekly VaR:
-13.01%
Monthly VaR:
-26.02%
How Much Can the price of
LMAT
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
-22%
Worst case (decline):
-90.15%
This translates to price declining to:
$38.45
This translates to price declining to:
$4.85
Severe Crash Probability
Risk of crash in next 6/12 months: High (50-70%)
What is Value at Risk (VaR)?
Risk Fundamentals
LMAT is a 83.68% riskier investment compared to the market/S&P 500 & is 57.35% riskier than Nasdaq (IXIC)
Risk (measured by volatility) is -0.85% below industry average
Overall, it is amongst the top 50% most risky stocks
Beta Examination of
LMAT
Beta in relation to market/S&P 500--1.19
Expected beta in 1 year's time:
0.846
Expected beta in 3 year's time:
1.196
Unlevered (debt free) Beta:
1.143
Beta in relation to Nasdaq (XNAS):
0.849
Beta in relation to all global stocks::
0.879
Beta Comparison & Analysis
Beta of competitors/peers::
1.286
Beta is -7.48% lower than peers
Average Industry Beta:
0.989
Beta is 20.30% above industry average
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
9.31%
Sustainable growth rate is -36.67% below industry average
Alpha provided | Alpha Analysis
Alpha provided:
0.108
Alpha is 127.80% above industry average alpha yield
Alpha is 690% higher than market/& is unsustainably high
Analysis of Cost of Capital of
LMAT
Equity cost of capital:
0.113
Equity cost of capital is 13.86% above industry mean WACC
Unlevered (without debt) cost of capital:
10.85%
Before-tax cost of debt:
11.23%
After-tax cost of debt:
8.88%
Overall debt rating:
Non-investment grade (junk/speculative grade
Weighted average cost of capital (WACC):
8.88%
WACC is 28.08% above industry mean WACC
Key Per-Share Metrics & Analysis
Revenue per share:
$7.20
Revenue growth rate per share of (3Y):
4.2
Annual revenue growth rate is -32.73% below industry average
EPS:
$1.24
Expected Annual growth rate of EPS (3Y):
11.16%
Expected future EPS growth rate is -3.48% lower than the Medical Instruments & Supplies industry
Free cash flow (FCF) per share:
$1.31
Balance sheet equity growth per share: 57.43%
Equity growth rate per share is 22080.97% higher than the industry
Debt per share
$0.62
EBITDA per share
$2.16
Valuation Analysis Today of
LMAT
P/E Ratio:
48.9
P/E Ratio of Competitors/Peers:
126.08
P/E ratio is -61.22% lower than main peers & is -1.98% lower than the industry
Stock price/value with industry average P/E ratio: $61.86
LMAT is -20.37% undervalued if valued using industry average P/E ratio
Share value as per dividend discount (DDM) model: $32.99
Present value of the expected future dividends only: $6.81
P/S (Price to Sales ratio):
6.84
Price to sales ratio is -7.73% below the industry mean
P/B (Price to book value ratio):
4.2
Price to free cash flow: 37.46
-
Net income growth rate (3Y):
7.68%
Net income growth rate is -107.27% lower than the industry average net income growth rate
Dividend Analysis
Dividend payout rate: 10.15%
Dividend yeild: 0.95%
Previous Dividend: $0.13
Previous adjusted dividend: $0.13
Previous Dividend: $0.47
Expected next dividend best case: $0.14
Expected next dividend worst case: $0.11
Average dividend payment (long-term): $0.11
Average dividend increase/decrease (growth rate) % per period: 4.12%
Expected next dividend payment date: 31/08/2022
Expected next dividend record date: 15/08/2022
Expected next dividend declaration date: 25/07/2022
Previous dividend payment date: 06/02/2022
Previous dividend record date: 17/05/2022
Previous dividend declaration date: 26/04/2022
Dividend History:
2022-05-16--$0.13
2021-11-18--$0.11
2021-05-18--$0.11
2022-03-07--$0.13
2021-08-25--$0.11
2021-03-08--$0.11
Dividend growth rate is -308.57% lower than the industry average
In-depth Debt & Leverage Analysis
Debt to equity ratio:
5.32%
Net debt to equity ratio:
0.01%
Debt to assets ratio:
4.69%
Net debt to assets ratio:
0.01%
Debt-to-asset ratio is -86.94% below industry average
Ability to repay debt:
Interest coverage ratio:
27.06
Interest coverage ratio is -61.85% less than industry average
Looking forward:
Debt growth rate:
-60.14%
Annual debt growth is -155% lower than industry average debt growth rate
Debt repayment rate in last quarter: 0.00%
Analysis of Key Statistics
Correlation of price movement with the market:
0.571
Statistical significance of correlation:
LMAT has a statistically significant correlation with the market
Average Correlation of the industry with the market:
0.505
Stock price is 13.17% more correlated with the market, compared to the industry average correlation
R Squared (percentage of price movement explained by movement of the market):
0.505
Correlation of price movement with Nasdaq (^IXIC):
0.001
Covariance of price movement with the market:
0.002
Kurtosis
7.813
Returns have a significant fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
Skewness of returns:
-0.479
Returns are, approximately, symmetrical
Fundamental Analysis & Dupont Analysis of
LMAT
Gross Profit Margin Ratio:
262%
Operating Profit Margin Ratio:
23.03%
Operating profit margin is 72.03% higher than the industry
Net Profit Margin Ratio:
262%
Effective Tax Rate:
22.35%
Effective tax rate is -32.01% lower than the industry
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
10.48%
Return on equity (ROE) is -122.98% lower than the industry
Financial Leverage
Asset Turnover Ratio (ROA):
9.24%
Return on assets (ROA) is 28.98% higher than the industry
Financial Leverage:
1.0x
Current Ratio:
7.74
Current ratio is 112.01% above industry average
Cash Conversion Cycle (days):
108.5
Cash conversion cycle is 105.84% above industry average
The remaining useful life of property plant & equipment is: 25.6 years
Stock based compensation to net income ratio:
4.32%
In-depth Efficiency Analysis
Revenue generated per employee:
351.3K
Each employee generates -1% less revenue than industry average revenue per employee
EBITDA generated per employee:
105.2K
Each employee generates -5% less EBITDA than industry average revenue per employee
Profit generated per employee:
60.0K
Each employee generates -23% less net income/profit than industry average revenue per employee
Free cash flow (FCF) generated per employee:
9.3K
Each employee generates -261% less free cash flow than industry average revenue per employee
Assets/Capital per employee
335.6K
Each employee generates -261% less free cash flow than industry average revenue per employee
Research & Development (R&D) Analysis
Research & development (R&D) investment growth rate-- 16.85%
Growth rate in R&D investment/expenditure is 6408.93% higher than the industry
Competitors/Peer firms of
LMAT
COHERUS BIOSCIENCES, INC. (XNAS:CHRS)
ZOGENIX, INC. (XNAS:ZGNX)
SCHOLAR ROCK HOLDING CORPORATION (XNAS:SRRK)
MERSANA THERAPEUTICS, INC. (XNAS:MRSN)
BIOLIFE SOLUTIONS, INC. (XNAS:BLFS)
MANNKIND CORPORATION (XNAS:MNKD)
CERUS CORPORATION (XNAS:CERS)
Mind Medicine (MindMed) Inc. (XNAS:MNMD)
Kinnate Biopharma Inc (XNAS:KNTE)
Current Analyst Ratings
Strong buy�4%
Buy�4%
Hold�25%
Sell�0%
Strong sell�0%
Overall analyst sentiment is: Hold
Income Statement
Period:
TTM
Date:
3/31/22
Revenue:
158.10M
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
54.56M
103.55M
11.89M
26.21M
55.25M
29.04M
-
67.14M
304.00K
1.75M
10.82M
47.36M
36.41M
27.02M
34.79M
7.77M
27.02M
Statement of Cash Flow
Date:
Period:
2.37M
Differed Income Tax :
-
Stock Based Compensation :
1.17M
Change in Working Capital :
- 4965.00K
Accounts Receivables:
- 1951.00K
Other Working Capital:
-
Other Non-Cash Items:
98.00K
Net Cash Provided by Operating Activities:
4.71M
Investments in PP&E:
- 536.00K
Net Acquisitions:
-
Purchases of Investments:
-
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
3/31/22
2022
Q1
15.56M
55.32M
70.88M
21.39M
41.35M
7.80M
141.41M
31.37M
65.95M
51.19M
-
1.98M
556.00K
151.04M
-
292.45M
2.19M
1.87M
1.21M
-
14.20M
18.27M
13.71M
2.63M
16.40M
-
34.67M
235.00K
91.42M
- 4624.0K
170.76M
March 31, 2022 at 6:00:00 AM
121.69M
257.79M
292.45M
-
15.58M
17.0K
-
-
- 536.00K
-
-
-
- 2743.00K
363.00K
- 2380.00K
- 90.00K
1.71M
15.56M
13.86M
4.71M
- 536.00K
4.18M
Our Proprietary Portfolio Rating
Our Rating:
D
Price Forecast/Expected Price in Next 5 Years of
LMAT
2023
2024
2025
2026
2027
$53.47
$101.03
$109.11
$117.84
$127.26